Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury

Table 2 Diverse effects of Helicobacter pylori infection on low-dose aspirin-induced gastroduodenal injury between Western countries and Japan n (%)

Ref.	Countries	Subjects	Study design	Outcomes	Prevalence of outcomes(H. pylori-positive vs -negative)
Kordecki et al[11], 1997	Poland	96 chronic LDA users	Observational	Endoscopic ulcers and erosions	49 (75) vs 11 (35)
Feldman et al[22], 2001	United States	61 healthy volunteers	Interventional study (LDA vs placebo)	Endoscopic ulcers and erosions	11 (50) vs 4 (16)
Lanas et al[23], 2002	Spain	245 chronic LDA users	Case-control	Upper gastrointestinal bleeding	88 (46) vs 10 (18)
Pilotto et al[12], 2004	Italy	245 chronic LDA users	Observational	Endoscopic ulcers	41 (37) vs 21 (16)
Hart et al[31], 2010	Australia, United Kingdom Canada, Spain,	206 chronic LDA users	Observational	Endoscopic erosions	27 (40) vs 78 (64)
Shiotani et al[15], 2009	Japan	305 chronic LDA users	Observational	Endoscopic ulcers	22 (13) vs 16 (12)
Tamura et al[18], 2011	Japan	150 asymptomatic chronic LDA users	Observational	Endoscopic ulcers	3 (4.4) vs 3 (3.7)
Watanabe et al[24], 2011	Japan	75 chronic LDA users	Observational	Endoscopic ulcers	7 (20) vs 8 (19)
Uemura et al[21], 2014	Japan	1454 chronic LDA users	Observational	Endoscopic ulcers	59 (8.4) vs 35 (4.6)
				Endoscopic erosions	132 (19) vs 293 (39)
Iijima et al[25], 2015	Japan	100 chronic LDA users	Observational	Endoscopic ulcers	10 (17) vs 5 (13)

H. pylori: Helicobacter pylori; LDA: Low-dose aspirin.